Propel Kinase Biology Understanding to Increase Selectivity, Overcome Resistance & Find the Optimal Combination Partner to Develop Best & First-in-Class Kinase Targeted Drugs
Join the 3rd Kinase Targeted Drug Discovery Summit
Attend the premier, target-specific conference designed to provide you withground-breaking insights to revolutionize your kinase biology
The kinase drug discovery field is at a pivotal moment, with recent breakthroughs from industry leaders such as Biogen, A-Alpha Bio, and Proxygen paving the way for exciting new approaches in targeting kinases, particularly in targeted protein degradation.
However, with ongoing challenges including selectivity and resistance in small molecule inhibitors, the 3rd Kinase Targeted Drug Discovery Summit will help you overcome these hurdles that limit the therapeutic applications and call for in-depth discussions focused on innovative future strategies for kinase targeted drugs.
What will you get?
- Discover cutting-edge developments in small molecule therapeutics, including PROTACs, molecular glues, and allosteric inhibitors
- Learn how to enhance drug selectivity, tackle resistance head-on, and identify optimal combination partners
- Lead the charge in creating first-class kinase-targeted drugs that can ultimately combat disease indications and transform patient outcomes!
Claim your FREE* ticket if you're a drug developer or researcher in the kinase community:
Showcase your work to 70+ Industry Peers!
We are calling for you to reveal novel insights across discovery, target identification and selection, translation, and clinical development to share modality-agnostic learnings and build recognition for your work from external leaders.
ATTENDANCE IS COMPLIMENTARY FOR DRUG DEVELOPERS & RESEARCHERS*
*Free access is only granted once approval of eligibility is confirmed - please visit the Registration page for terms and conditions
2025 World-Class Speaker Faculty Includes
Matthew L. Meyerson
Director & Professor - Pathology, Medical Oncology & Center Cancer Genome Discovery
Dana-Farber / Harvard Cancer Center
Who Attends This Meeting
What Your Peers Have to Say
"The quality of the presentations was very high – I got the opportunity to meet potential new collaborators"
"It was a great blend of industry and academic researchers, alongside vendors truly enabling new technologies"
“The size of the meeting was just right to interact and network with everyone in the kinase community”
2025 Partners
